Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Januar 2026 10:23 ET | Quelle: Research and Markets

Cell Therapy Collaboration and Licensing Agreements Trends Report 2025 with Directory of 989 Deals - Upfront, Milestone, Royalties, Company A-Z, Deal Type and Therapy Area

Dublin, Jan. 29, 2026 (GLOBE NEWSWIRE) -- The "Cell Therapy Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering. This report contains a...
29. Januar 2026 06:00 ET | Quelle: OMEICOS Therapeutics GmbH

OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD)

OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD)
28. Januar 2026 10:30 ET | Quelle: Steadman Philippon Research Institute

Steadman Philippon Research Institute and Vail Health Renew Landmark Partnership with 5-Year Commitment

Vail, Colorado, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Steadman Philippon Research Institute (SPRI) and Vail Health have renewed their longstanding partnership with a new five-year agreement advancing...
21. Januar 2026 09:30 ET | Quelle: John Snow Labs

Redefining Real-World Evidence: John Snow Labs Introduces First FDA-Ready Patient Journey Platform

Designed for secondary use of multimodal, longitudinal patient data, PJI embeds regulatory-grade governance and transparency into every patient journey.
12. Januar 2026 09:13 ET | Quelle: Global Alzheimer’s Platform Foundation®

Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with Spear Bio for the Transformative Bio-Hermes-002 Study

WASHINGTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Spear Bio, a biotechnology company pioneering wash-free ultrasensitive...
18. Dezember 2025 07:00 ET | Quelle: BioStem Technologies, Inc.

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
11. Dezember 2025 09:29 ET | Quelle: NeXtGen Biologics

NeXtGen™ Biologics Secures Favorable Outcome in Inter-Partes Patent Review

NeXtGen™ Biologics Secures Favorable Outcome in Inter-Partes Patent Review
26. November 2025 07:15 ET | Quelle: Research and Markets

Monoclonal Antibody Collaboration and Licensing Agreements Trends Analysis Report 2025 with Directory of 670 Deals Signed Since 2019 by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Monoclonal Antibody Collaboration and Licensing Deals 2019-2025" has been added to ResearchAndMarkets.com's offering.This report contains a...
20. November 2025 08:00 ET | Quelle: Medela

Medela’s 2025 Global Breastfeeding & Lactation Symposium Series Unites Experts Across Three Continents to Advance Maternal and Infant Health

Baar, Switzerland, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Medela, a global leader in breast milk and healthcare technology, continues its legacy of advancing lactation science and clinical education...
18. November 2025 04:16 ET | Quelle: Research and Markets

Pharmaceuticals and Biotechnology Option and Evaluation Deals Trends Analysis Report 2025 with Directory of Deals by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2019-2025" report has been added to ResearchAndMarkets.com's offering.Fully revised...

Nächste Seite